Breaking News

COVID-19 Vaccine Candidate Activates Both B and T-cell Arms of the Immune System

February 12, 2022 • 2:02 pm CST
(Precision Vaccinations News)

Texas-based Vaxxinity, Inc. announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple SARS-CoV-2 virus variants of concern (VoC).

Vaxxinity's press release issued on February 11, 2022, stated UB-612 generated more than three-times higher titers of neutralizing antibodies against the Omicron variant than an approved mRNA vaccine with boosters.

Sera from 92 participants from UB-612's Phase 2 study, including eight placebos (randomized and tested blinded) and up to 36 participants in the Phase 1 study, half of the latter boosted with a third dose of UB-612, were used in these studies to analyze binding of IgG and neutralization against multiple VoCs and Variants including Omicron.

UB-612 is the first multitope protein/peptide-based vaccine candidate for SARS-CoV-2.

The vaccine candidate is designed to activate both B and T-cell arms of the immune system. 

"The ability of these sera to neutralize Omicron at these high levels is extraordinary and unprecedented considering that Omicron has more than 30 potential immune evading mutations and deletions across its spike protein, 15 of which are in the RBD region where our UB-612 vaccine is directed."

"Such data show that UB-612 could potentially be a unique vaccine candidate that is highly effective at mobilizing the immune system against a broad range of both current and future SARS-CoV-2 variants," said Farshad Guirakhoo, Ph.D., Chief Scientific Officer at Vaxxinity.

The studies were conducted by David Goldblatt, M.B. Ch.B., Ph.D., at University College London and VisMederi, a Coalition for Epidemic Preparedness Innovations-centralized laboratory.

Vaxxinity confirmed plans to publish these UB-612 data and present the findings at World Vaccine Congress in April 2022. 

Vaxxinity, Inc. is a purpose-driven biotechnology company located in Dallas, TX, committed to democratizing healthcare globally.

Our Trust Standards: Medical Advisory Committee

Share